What drug has been shown to be as effective as Ranibizumab in the treatment of neovascular AMD when injected bimonthly?

Aflibercept is the drug that has been shown to be as effective as Ranibizumab in the treatment of neovascular age-related macular degeneration (AMD) when injected bimonthly. This efficacy is significant as both treatments aim to inhibit the formation of abnormal blood vessels and reduce fluid leakage, which are critical aspects of managing neovascular AMD.

Aflibercept works by functioning as a vascular endothelial growth factor (VEGF) inhibitor, similar to Ranibizumab. Clinical studies have demonstrated that bimonthly injections of Aflibercept can result in visual acuity and anatomical outcomes that are comparable to those achieved with Ranibizumab. This aligns with treatment protocols that seek to minimize the frequency of injections while maintaining therapeutic effectiveness.

In the context of treatment alternatives, Bevacizumab, although similar in function, is not specifically indicated for intravitreal use and lacks the robust data regarding its effectiveness tailored specifically for AMD compared to Ranibizumab and Aflibercept. Faricimab represents a newer class of treatments but was not the focus of comparisons in this context. Maribavir is unrelated to the treatment of AMD and is used for viral infections, further clarifying why it’s not applicable here.